Induction of interferon regulatory factors, 2′-5′ oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness

British Journal of Haematology

Volumn 92, Issue 3, 1996, Pages 595-603

  Fischer, Thomas ^a,b   Aman, Javad ^a   Van Der Kuip, Heiko ^a   Rudolf, Gregor ^a   Peschel, Christian ^a   Aulitzky, Walter E ^a   Huber, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clinical responsiveness; CML; IFN alpha and IFN beta therapy; mRNA induction of IFN stimulated genes

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; BETA INTERFERON; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA; RECOMBINANT ALPHA2B INTERFERON; RIBONUCLEASE L; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

2',5'-OLIGOADENYLATE SYNTHETASE; BLOTTING, NORTHERN; DNA-BINDING PROTEINS; EIF-2 KINASE; ENDORIBONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; TREATMENT FAILURE;

EID: 0029993731     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.00392.x     Document Type: Article

References (42)

1. Aman, J., Keller, U., Derigs, D., Mansour, M., Huber, C. & Peschel, C. (1993a) Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood, 84, 4142-4150.
2. Aman, J., Rudolf, G., Goldschmitt, J., Aulitzky, W.E., Lam, C., Huber, C. & Peschel, C. (1993b) Type-1 interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood, 82, 2371-2378.
3. Aulitzky, W.E., Peschel, C., Depres, D., Aman, J., Trautmann, P., Tilg, H., Rudolf, G., Hüttmann, H., Obermaier, J., Herold, M. & Huber, C. (1993) Divergent in vivo and in vitro antileukemic activity of recombinant interferon-beta in patients with chronic-phase chronic myelogenous leukemia. Annals of Hematology, 67, 205-211.
4. Chong, K.L., Schappert, K., Meurs, E., Feng, G., Donahue, T.F., Friesen, J.D., Hovanessian, A.G. & Williams, B.R.G. (1992) Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO Journal, 11, 1553-1562.
5. Clauss, I.M., Vandenplas, B., Wathelet, M.G., Dorval, C., Delforge, A., Content, J., Stryckmans, P. & Huez, G.A. (1990) Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-alpha treatment. Blood, 76, 2337-2342.
6. bcr-abl gene of the Philadelphia chromosome. Science, 247, 824-830.
7. Deisseroth, A.B., Andreff, M. & Champlin, R. (1993) Chronic leukemias. Cancer: Principles and Practice of Gncology (ed. by V. De Vita, S. Hellman and S. A. Rosenberg), p. 1965. Lippincott, Philadelphia.
8. Fialkow, P.J., Denman, A.M., Jakobson, R.J. & Lowenthal, M.N. (1979) Chronic myelocytic leukemia: origin of some lymphocytes from the leukemic stem cell. Journal of Clinical Investigation, 62, 815-823.
9. Fialkow, P.J., Jacobson, R.J. & Papayannopolou, T. (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. American Journal of Medicine, 63, 125-130.
10. Fischer, T., Wiegmann, K., Böttinger, H., Morens, K., Burmester, G. & Pfizenmaier, K. (1990) Regulation of IFN-gamma-receptor expression in human monocytes by GM-CSF. Journal of Immunology, 145, 2914-2919.
11. Fujita, T., Kimura, Y., Miyamoto, M., Barsoumian, F. & Taniguchi, T. (1989) Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature, 337, 270-272.
12. Gordon, M.Y., Atkinson, J., Clarke, D., Dowding, C.R., Goldman, J.M., Grimsley, P.G., Siczkowski, M. & Greaves, M.F. (1991) Deficiency of a phosphatidylinositol anchored cell adhesion molecule influences hematopoietic progenitor binding to marrow stroma in chronic myeloid leukemia. Leukemia, 5, 693-698.
13. Gutch, M.J. & Reich, N.C. (1991) Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proceedings of the National Academy of Sciences of the United States of America, 88, 7913-7917.
14. Haque, S.J. & Williams, B.R.G. (1994) Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-alpha. Journal of Biological Chemistry, 269, 19523-19529.
15. Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T. & Taniguchi, T. (1989) Structurally similar but functionally distinct factors. IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell, 58, 729-739.
16. Harada, H., Kitagawa, M., Tanaka, N., Yamamoto, H., Harada, K., Ishihara, M. & Taniguchi, T. (1993) Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science, 259, 971-974.
17. Hassel, B.A., Zhou, A., Sotomayor, C., Maran, A. & Silverman, R.H. (1993) A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO Journal, 12, 3297-3304.
18. Hovanessian, A.G. (1989) The double-stranded RNA-activated protein kinase induced by interferon: dsRNA-PK. Journal of Interferon Research, 9, 641-647.
19. Howard, O.M., Talpaz, M., Kantarjian, H., Seong, D., Wedrychowski, A., Paslidis, N., Hester, J., Cork, A., Turpin, J., Lopez-Berestein, G., Trujillo, J., Gutterman, J., Freireich, E. & Deisseroth, A. (1990) Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Blood, 76, 1117-1130.
20. Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K., Thierfelder, W.E., Kreider, B. & Sivennoinen, O. (1994) Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends in Biological Science, 19, 222-227.
21. Kalvakolanu, D.V.R., Bandyopadhyay, S.K., Harter, M.L. & Sen, G.C. (1991) Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proceedings of the National Academy of Sciences of the United States of America, 88, 7459-7463.
22. Kanda, K., Decker, T., Aman, P., Wahlström, M., von Gabain, A. & Kallin, B. (1992) The EBNA2-related resistance towards a interferon in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Molecular and Cellular Biology, 12, 4930-4936.
23. Kessler, D., Pine, R., Pfeffer, L., Levy, D. & Darnell, J.E. (1988) Cells resistant to interferon are defective in activation of a promotor-binding factor. EMBO Journal, 7, 3779-3783.
24. Lanza, F., Bi, S., Castoldi, G. & Goldman, J.M. (1993) Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia, 7, 1570-1575.
25. Lengyel, P. (1993) Tumor-suppressor genes: news about the interferon connection. Proceedings of the National Academy of Sciences of the United States of America, 90, 5893-5895.
26. Meurs, E.F., Galabru, J., Barber, G.N., Katze, M.G. & Hovanessian, A.G. (1993) Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America, 90, 232-236.
27. Osterholz, J., Dowding, C., Guo, A.P., Siczkowski, M. & Goldman, J.M. (1991) Interferon-alpha alters the distribution of CFU-GM between the adherent and nonadherent compartments in long term cultures of chronic myeloid leukemia marrow. Experimental Hematology, 19, 326-331.
28. Peschel, C., Aman, J., Rudolf, G., Aulizky, W.E. & Huber, C. (1993) Regulation of the cytokine network by interferon: a potential mechanism of interferon in chronic myelogenous leukemia. Seminars in Hematology, 30, 28-31.
29. Pine, R., Decker, T., Kessler, D., Levy, D. & Darnell, J.E. (1990) Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promotors of both alpha-interferon- and interferon-stimulated genes but is not a primary transcriptional activator of either. Molecular and Cellular Biology, 10, 2448-2457.
30. Platanias, L.C., Pfeffer, L.M., Barton, K.P., Vardiman, J.W., Golomb, H.M. & Colamonici, O.R. (1992) Expression of the IFN-alpha receptor in hairy cell leukaemia. British Journal of Haematology, 82, 541-546.
31. Rowley, J.D. (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293.
32. Savary, C.A. & Lotzova, E. (1989) Natural killer cell mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias. Experimental Hematology, 17, 183-187.
33. Sen, G.C. & Lengyel, P. (1992) The interferon system. Journal of Biological Chemistry, 267, 5017-5020.
34. Sims, S.H., Cha, Y., Romine, M.F., Gao, P.Q., Gottlieb, K. & Deisseroth, A.B. (1993) A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promotor. Molecular and Cellular Biology, 13, 690-702.
35. Subel, F.M., Brent, R., Kingston, R.E., Mooree, D.D., Seidmann, J.G., Smith, J.A. & Struhl, K. (1987) Current Protocols in Molecular Biology, Vol. 1, p. 1:4.2.4. Wiley, New York.
36. Talpaz, M., Chernajovsky, Y., Troutman-Worden, K., Wetzler, M., Kantarjian, H. Gutterman, J.U. & Kurzrock, R. (1992) Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Research, 52, 1087-1090.
37. Talpaz, M., Kantarjian, H.M., McCredie, K., Trujillo, J.M., Keating, M.J. & Gutterman, J.U. (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon-alpha in CML. New England Journal of Medicine, 314, 1065-1069.
38. Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J.M. & Gutterman, J.U. (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Annals of Internal Medicine, 114, 532-538.
39. Thaler, J., Gastl, G., Fluckinger, T., Niederwieser, D., Huber, H., Seewann, H., Silly, H., Lang, A., Abbrederis, C. & Gadner, H. (1993) Treatment of chronic myelogenous leukemia with Interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Seminars in Hematology, 30, 17-19.
40. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine, 330, 820-825.
41. Wilman, C.L., Sever, C.E., Pallavicini, M.G., Harada, H., Tanaka, N., Slovak, M.L., Yamamoto, H., Harada, K., Meeker, T.C., List, A.F. & Taniguchi, T. (1993) Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science, 259, 968-971.
42. Zhou, A., Hassel, B.A. & Silverman, R.H. (1993) Expression cloning of 2-5A-dependent RNase a uniquely regulated mediator of interferon action. Cell, 72, 753-765.